Isofol Medical AB
5IU
Company Profile
Business description
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
Contact
Arvid Wallgrens Backe 20
Biotech Center
GothenburgSE-413 46
SWET: +46 31137331
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
stocks
Reporting season was stronger than share prices suggest
What 164 ASX earnings results revealed.
stocks
How Anthropic makes money—and what investors should know ahead of its IPO filing
Part one of a two-part Q&A with PitchBook senior analyst Harrison Rolfes on Anthropic’s business model and why it needs to grow margins, fast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,197.90 | 37.50 | 0.41% |
| CAC 40 | 8,280.63 | 21.22 | -0.26% |
| DAX 40 | 25,839.33 | 130.78 | -0.50% |
| Dow JONES (US) | 53,061.95 | 295.07 | 0.56% |
| FTSE 100 | 10,756.45 | 32.83 | -0.30% |
| HKSE | 25,403.86 | 92.65 | 0.37% |
| NASDAQ | 26,217.83 | 118.05 | 0.45% |
| Nikkei 225 | 64,455.83 | 130.19 | 0.20% |
| NZX 50 Index | 13,911.48 | 19.09 | -0.14% |
| S&P 500 | 7,666.60 | 35.13 | 0.46% |
| S&P/ASX 200 | 9,016.20 | 42.20 | 0.47% |
| SSE Composite Index | 3,960.28 | 18.90 | 0.48% |